Technology Networks spoke to Professor Thomas Rademacher, co-founder, executive director and CEO at Gylden Pharma Limited, to ...
Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...
Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
GlobalData on MSN23h
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitugSanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 11,687.23 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback